$11.3M
$3.4M
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
Wound Treatment Device Manufacturer. FDA-approved acoustic wound therapy device with 44 issued patents generated $11.3M in 2024 revenue, with over 20 additional healthcare technologies in the pipeline.
Why we like it
- Earnings quality is strong with $3.35M EBITDA on $11.3M revenue, a roughly 30 percent margin that is rare for a manufacturer and signals genuine pricing power. The margin profile points to differentiated, patent-protected product economics rather than contract or commodity manufacturing where margins get squeezed to single digits.
- The moat is real and legally enforceable, anchored by 44 issued patents plus FDA approval that competitors cannot replicate without years of clinical work and capital. This combination of regulatory clearance and IP protection is exactly the kind of durable barrier that lets a small business hold share and price against larger entrants.
- Wound care rides demographic tailwinds that are independent of the economic cycle, driven by an aging population and rising diabetes, obesity, and vascular disease. Demand for chronic wound treatment grows structurally every year and is reimbursed by payers, which insulates revenue from consumer discretionary swings.
- There is embedded optionality in the 20-plus technologies in the pipeline, none of which appear monetized in the current $11.3M revenue base. An operator who can navigate FDA pathways and commercialization could turn this into a multi-product platform, meaning you are buying current cash flow plus a free call option on the roadmap.
How to improve it
- Audit the commercial engine in the first 90 days to understand whether sales are clinician-driven, distributor-led, or direct to facilities. Most device companies this size under-invest in sales infrastructure, and a defined territory plan with quota-carrying reps can accelerate adoption of an already-approved product.
- Map the reimbursement landscape and lock in CPT codes, coverage policies, and payer relationships. Wound care economics live and die on reimbursement, and tightening or expanding covered indications directly drives unit volume and protects against pricing pressure.
- Prioritize the pipeline of 20-plus technologies by FDA pathway, addressable market, and capital required, then sequence two or three for commercialization. Treating the pipeline as a portfolio rather than a backlog turns dormant IP into the next revenue leg without diluting focus.
- Pursue durable medical equipment and long-term care channel expansion beyond acute hospital settings. Skilled nursing facilities and home health represent large, fragmented wound care demand that a single-product device company often under-penetrates.
- Defend and extend the patent estate by filing continuations and securing international protection where the device is sold or could be sold. The 44 patents are the core asset value, and lapsing or geographically thin coverage is a silent risk to the moat.
- Build a recurring revenue layer through consumables, applicators, or service contracts attached to each device. Converting one-time hardware sales into razor-and-blade economics raises customer lifetime value and smooths revenue.
Diligence notes
- Verify the FDA clearance type (510(k) versus PMA), the cleared indications, and whether the approval is held by the company and transferable in a sale. The entire thesis depends on that clearance being valid, current, and assignable to a buyer.
- Confirm the 44 patents are issued, owned by the company free of liens, and have meaningful remaining life. Pull a patent schedule and have IP counsel assess enforceability and expiration timing, since patents near expiry materially weaken the moat.
- Examine customer concentration and the contract structure with hospitals, clinics, and distributors. A 30 percent margin medtech business can hide single-customer or single-GPO dependence that would change the risk profile entirely.
- Pressure test the $11.3M revenue and $3.35M EBITDA against audited or reviewed financials, and separate recurring device sales from any one-time or grant revenue. Confirm how much R&D and regulatory spend on the pipeline is expensed in the current EBITDA figure.
- Investigate reimbursement and regulatory risk, including any payer coverage changes, recalls, adverse event reports, or pending FDA correspondence. A single coverage downgrade or quality issue can impair revenue and command attention immediately post-close.
- Clarify why the owner is selling and how much of the business depends on a key inventor, regulatory lead, or clinical champion. For an IP-driven medtech company, loss of the technical founder is a real transition risk that must be addressed in the deal structure.